Staccato Loxapine Pulmonary Safety in Patients With COPD
| Status: | Completed |
|---|---|
| Conditions: | Chronic Obstructive Pulmonary Disease, Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 40 - 65 |
| Updated: | 3/15/2017 |
| Start Date: | June 2009 |
| End Date: | August 2009 |
Pulmonary Safety of Staccato® Loxapine for Inhalation in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study is to assess the pulmonary safety of 2 doses of Staccato Loxapine
within a day in patients with COPD.
within a day in patients with COPD.
Inclusion Criteria:
- History of COPD for at least 6 months with pre-bronchodilator FEV1 ≥40% of predicted
value and >15 pack-year history of cigarette smoking.
Exclusion Criteria:
- History of asthma, or any other acute or chronic pulmonary disease.
We found this trial at
1
site
Click here to add this to my saved trials
